UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO 13 or 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 5, 2004
NOVAVAX, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 0-26770 | 22-2816046 | ||
| (State or other jurisdiction of | (Commission | (I.R.S. Employer | ||
| incorporation or organization) | File No.) | Identification No.) |
| 8320 Guilford Road, Columbia, MD | 21046 | |
| (Address of principal executive offices) | (Zip code) |
(301) 854-3900
Registrant’s telephone number, including area code
Not applicable
(Former name or former address, if changed since last report)
NOVAVAX, INC.
ITEMS TO BE INCLUDED IN THIS REPORT
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
99.1 Press Release dated May 5, 2004.
ITEM 12. RESULTS OF OPERATONS AND FINANCIAL CONDITION.
On May 5, 2004, Novavax, Inc. reported its first quarter earnings for 2004.
A copy of the Press Release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| NOVAVAX, INC. | ||||
| Date: May 5, 2004 | By: | /s/ Dennis W. Genge Dennis W. Genge Vice President and Chief Financial Officer |